Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

GlobeNewswireFeb 27 07:30 ET

Express News | Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

BenzingaFeb 26 18:05 ET

Cognition Therapeutics Analyst Ratings

BenzingaFeb 26 18:04 ET · Ratings

$CGTX Stock Is up 17% Today. Here's What We See in Our Data.

Quiver QuantitativeFeb 26 10:31 ET

Express News | Cognition Therapeutics Says Masked Analysis Showed Participants Receiving Oral Zervimesine For At Least Least 6 Months Experienced Slower Lesion Growth Than Participants Receiving Placebo

BenzingaFeb 26 07:08 ET

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

GlobeNewswireFeb 26 07:00 ET